Menu
Back to Journals » Drug Design, Development and Therapy » Volume 9
Sphingosine kinase 1 as an anticancer therapeutic target
Authors Gao Y, Gao F, Chen K, Tian M, Zhao D
Received 21 February 2015
Accepted for publication 29 April 2015
Published 23 June 2015 Volume 2015:9 Pages 3239—3245
DOI https://doi.org/10.2147/DDDT.S83288
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Professor Shu-Feng Zhou
Ying Gao,1,* Fei Gao,2,* Kan Chen,3,* Mei-li Tian,1 Dong-li Zhao1
1Department of Radiotherapy Oncology, First Affiliated Hospital of Xi’an Jiaotong University, 2Department of Neurology, First Affiliated Hospital of Xi’an Medical University, Xi’an, 3School of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, People’s Republic of China
*These authors contributed equally to this work
Abstract: The development of chemotherapeutic resistance is a major challenge in oncology. Elevated sphingosine kinase 1 (SK1) levels is predictive of a poor prognosis, and SK1 overexpression may confer resistance to chemotherapeutics. The SK/sphingosine-1-phosphate (S1P)/sphingosine-1-phosphate receptor (S1PR) signaling pathway has been implicated in the progression of various cancers and in chemotherapeutic drug resistance. Therefore, SK1 may represent an important target for cancer therapy. Targeting the SK/S1P/S1PR signaling pathway may be an effective anticancer therapeutic strategy, particularly in the context of overcoming drug resistance. This review summarizes our current understanding of the role of SK/S1P/S1PR signaling in cancer and development of SK1 inhibitors.
Keywords: sphingosine kinase 1, S1P, S1PR, inhibitors, cancer, therapy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.